Recent events
Recent events tied to this brand in public sources.
Back to profile10 entries
2022
Eisai receives Tokyo Governor Prize for Corporate Governance
Eisai was selected as the winner of the Tokyo Governor Prize for Corporate Governance of the Year 2021. The award ceremony was held on January 31, 2022.
2021
Eisai and Arena Pharmaceuticals sued over Belviq
A plaintiff and his deceased wife sued Eisai and Arena Pharmaceuticals in the District of New Jersey, alleging that the companies knew or should have known that Belviq could pose a cancer risk. The complaint included product-liability and other claims; the allegations are not presented as a court determination.
2021
FDA approves Keytruda and Lenvima combination for advanced kidney cancer
The FDA approved MSD's Keytruda and Eisai's Lenvima combination as first-line treatment for adults with advanced renal cell carcinoma.
2021
FDA approves Keytruda–Lenvima combination for advanced endometrial carcinoma
The U.S. Food and Drug Administration approved Keytruda in combination with Lenvima for certain patients with advanced endometrial carcinoma following prior systemic therapy who are not candidates for curative surgery or radiation.
2021
Eisai receives Japan Corporate Philanthropy Award
Eisai received the 18th Corporate Philanthropy Award (FY 2020) from the Japan Philanthropic Association. The presentation ceremony took place on February 19, 2021.
2021
Eisai launches Equfina in South Korea
Eisai launched Equfina, a treatment for Parkinson’s disease, in South Korea. The article describes it as the first launch of Equfina in Asia outside Japan.
2020
Eisai launches DAYVIGO in the United States
Eisai's U.S. subsidiary launched DAYVIGO (lemborexant), a treatment for adults with insomnia, in the United States on June 1, 2020.
2020
Eisai applies to withdraw Belviq in the United States
Eisai applied to voluntarily withdraw Belviq and its extended-release form in the United States after the FDA requested withdrawal, concluding that potential risks outweighed benefits based on long-term trial data. Eisai said it interpreted the data differently, respected the FDA's decision, and was working on the withdrawal process.
2020
Eisai voluntarily withdraws Belviq
Eisai said it agreed to voluntarily withdraw Belviq and Belviq XR from the U.S. market at the FDA’s request after study data showed a higher cancer rate among participants taking Belviq. Eisai said it disagreed with the FDA’s interpretation of the safety data.
2019
BioArctic and Eisai initiate BAN2401 research collaboration
BioArctic announced that it had initiated a research collaboration with Eisai to further study the profile of the investigational drug candidate BAN2401. The program was planned to continue through the end of June 2021.